调查研究
Dai Zhijun①;Wang Xijing①;Liu Xiaoxu①;Wu Wenying②;Ji Zongzheng③;Kang Huafeng①;Xue Fengjie①;
Xue Xinghuan①
2006, 8(4): 262-265.
Objective:To evaluate the adverse effects of three different regimens in order to provide a basis for selection one of them used as neoadjuvant chemotherapy for local advanced breast cancer.Methods:During the period 2000-2005,a retrospective study was done for adverse effects and short-term efficacy to the three regimens in 89 patients with local advanced cancer.The 89 patients were assigned to 3 chemotherapy groups:CEF group(cyclophosphamide + epirubicin + fluorouracil,36 cases),NEF group(vinorelbine + epirubicin + fluorouracil,32 cases),TAC group(docetaxel + epirubicin + cyclophosphamide,21 cases),and treated with one of the three regimens for 2 cycles,every cycle was 28 d.Results:①The response rate(RR)of the breast primary tumor in CEF,NEF,and TAC groups was 47.2 %(17/36),71.9 %(23/32)and 85.7 %(18/21),respectively.The difference of response rate between CEF group and NEF group was significant(x2=4.251,P< 0.05)and so was between CEF group and TAC group(x2=8.292,P=0.004).But there was no difference between NEF group and TAC group(x2=1.386,P>0.05).② The adverse reactions of TAC group were leukopenia(21/21,100%),alopecia(21/21,100%),arthralgia or myalgia(12/21,51.1%),flash of face(9/21,42.9%)and hypersensitivity(4/21,19%).The incidence of leukopenia to TAC group was obviously higher than that in CEF group and NEF group.Thirteen of 32 cases in NEF group developed peripheral phlebitis(40%).Some other adverse reactions such as decreased hemoglobin level,thrombocytopenia,and gastrointestinal lesions were similar in the three group.Conclusion:NEF is an effective and tolerable regimen for treatment of patients with local advanced breast tumor.
